IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Paragon Capital Management Inc.

Paragon Capital Management Inc. boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,820 shares of the company’s stock after purchasing an additional 782 shares during the quarter. IDEXX Laboratories comprises approximately 1.2% of Paragon Capital Management Inc.’s investment portfolio, making the stock its 29th largest position. Paragon Capital Management Inc.’s holdings in IDEXX Laboratories were worth $1,579,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Ninety One SA PTY Ltd raised its stake in IDEXX Laboratories by 8.3% in the 4th quarter. Ninety One SA PTY Ltd now owns 4,457 shares of the company’s stock valued at $1,843,000 after purchasing an additional 341 shares during the last quarter. Ninety One UK Ltd increased its stake in shares of IDEXX Laboratories by 42.1% in the 4th quarter. Ninety One UK Ltd now owns 71,032 shares of the company’s stock worth $29,367,000 after acquiring an additional 21,041 shares during the last quarter. E. Ohman J or Asset Management AB increased its stake in shares of IDEXX Laboratories by 13.6% in the 4th quarter. E. Ohman J or Asset Management AB now owns 3,750 shares of the company’s stock worth $1,550,000 after acquiring an additional 450 shares during the last quarter. Western Pacific Wealth Management LP acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth $84,000. Finally, SYM FINANCIAL Corp acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth $553,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of recent research reports. Stifel Nicolaus cut their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. JPMorgan Chase & Co. cut their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Finally, Leerink Partners assumed coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $524.38.

Insider Transactions at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.18% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $465.03 on Wednesday. The stock has a 50-day simple moving average of $424.92 and a 200-day simple moving average of $453.54. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The stock has a market capitalization of $38.08 billion, a PE ratio of 44.84, a PEG ratio of 3.64 and a beta of 1.37. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.